Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.84 |
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.62 |
| ▸ | METAP2 | P50579 | 2/20 | 0.62 |
| ▸ | METAP1 | P53582 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.59 |
| ▸ | G6PD | P11413 | 2/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.59 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578880 | 0.86 | KEAP1 (0.76) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL164503 | 0.86 | RECQL (0.76) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7537943 | 0.86 | RECQL (0.76) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7573136 | 0.86 | KEAP1 (0.76) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7196466 | 0.86 | KMT2A (0.75) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL29958089 | 0.86 | RECQL (0.74) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7536143 | 0.84 | RECQL (0.71) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL9942077 | 0.83 | RECQL (0.71) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL18434691 | 0.82 | KEAP1 (0.78) | RECQLKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL163325 | 0.82 | RECQL (0.69) | RECQLKMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0542556-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1995-07-19 | — | — | EP | claimed |
| EP-4082538-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE MEDICINE (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20220227750-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ANAPHYLAXIS | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-21 | — | — | US | disclosed |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3021839-B1 | COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE MEDICINE (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3021840-B1 | COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE MEDICINE (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-104969406-B | Electrolyte solution for electrochemical device and electrochemical device | 富士胶片和光纯药株式会社 | 2018-11-02 | — | — | CN | disclosed |
| US-10112933-B2 | Methods and compositions for treatment of fibrosis | BAYLOR COLLEGE OF MEDICINE (US) | 2018-10-30 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| WO-2009149192-A1 | STAT3 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| WO-1999041756-A1 | INTRINSICALLY CONDUCTIVE POLYMER BLENDS HAVING A LOW PERCOLATION THRESHOLD | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-08-19 | — | — | WO | disclosed |
| US-5908898-A | ELECTRICALLY INSULATIVE THERMOPLASTIC MATRIX POLYMER DISPERSED THROUGH AN INTRINSICALLY CONDUCTIVE POLYMER SALT THAT IS INCOMPATIBLE WITH THE MATRIX POLYMER, A THERMOPLASTIC CONDUCTIVE PHASE POLYMER THAT IS PARTIALLY COMPATIBLE WITH | MONSANTO COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1999019391-A1 | INTRINSICALLY CONDUCTIVE POLYMER/PLASTICIZER BLENDS WITH ENHANCED CONDUCTIVITY | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-04-22 | — | — | WO | disclosed |
| US-5871671-A | Intrinsically conductive polymer/plasticizer blends with enhanced conductivity | MONSANTO COMPANY (US) | 1999-02-16 | — | — | US | disclosed |
| US-4471104-A | SELF EXTINGUISHING | BAYER AKTIENGESELLSCHAFT (DE) | 1984-09-11 | — | — | US | disclosed |
| EP-0082383-A1 | Process for preparing polycarbonates containing sulfone anilide end groups | BAYER AG (DE) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112933-B2 | Methods and compositions for treatment of fibrosis | STAT3, MMP1, MMP8 | RECQL 3447/4885KMT2A 2075/4885ALDH1A1 956/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | RECQL 3933/4885KMT2A 1055/4885ALDH1A1 3308/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | RECQL 3933/4885KMT2A 1055/4885ALDH1A1 3308/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | RECQL 4410/4885KMT2A 1456/4885ALDH1A1 2446/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | RECQL 3933/4885KMT2A 1055/4885ALDH1A1 3308/4885 |
| US-20220227750-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ANAPHYLAXIS | CMA1, CPA3, STAT6 | RECQL 2205/4885KMT2A 453/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.